PT - JOURNAL ARTICLE AU - Allen, Lucy AU - Battle, Mark AU - Goggi, Julian AU - Contreras Brava, Luisa AU - Cooper, Joanne AU - Lear, Rochelle AU - Durrant, Clare TI - Monitoring tumour response to anti-angiogenic therapy with an F18-labeled angiogenesis imaging agent DP - 2009 May 01 TA - Journal of Nuclear Medicine PG - 450--450 VI - 50 IP - supplement 2 4099 - http://jnm.snmjournals.org/content/50/supplement_2/450.short 4100 - http://jnm.snmjournals.org/content/50/supplement_2/450.full SO - J Nucl Med2009 May 01; 50 AB - 450 Objectives The RGD-binding integrins αvβ3 and αvβ5, play key roles in tumour angiogenesis. We examined an [18F] labeled small peptide (AH111585) containing an RGD (Arg-Gly-Asp) sequence. AH111585 binds with high affinity (nM) to αvβ3 and αvβ5 integrins, which are highly expressed on tumour neovasculature. In this study, [18F]AH111585 was used to examine the response of human glioblastoma xenografts to treatment with anti-angiogenic therapy. Methods U87 tumour uptake of [18F]AH111585 was determined by microPET imaging (% id/g) following administration of anti-angiogenic therapies, such as Sutent and Avastin. Tumour microvessel density (MVD) was also analysed post-therapy. Results Dymanic mircoPET imaging of [18F]AH111585 uptake demonstrated that tumour uptake peaked ~30 mins post-injection of the tracer (5% id/g). Whole body biodistribution studies confirmed rapid clearance of [18F]AH111585 from the blood with predominantly urinary excretion. Following administration of a clinically relevant anti-angiogenic therapy, a reduction in [18F]AH111585 tumour uptake was demonstrated compared to vehicle controls. Skeletal muscle, used as a reference tissue, demonstrated equivalent [18F]AH111585 uptake pre- and post-therapy. A reduction in MVD was also seen in anti-angiogenic therapy treated tumours. Conclusions The data demonstrate that [18F]AH111585 can detect changes in tumour uptake following acute anti-angiogenic therapy. The results suggest this imaging agent may provide clinically important information to guide patient management and monitor response to anti-angiogenic therapies.